Sareum (LON:SAR) Shares Down 4.3% – What’s Next?

Sareum Holdings plc (LON:SAR) shares dropped 4.3% during mid-day trading on Friday . The stock traded as low as GBX 21 and last traded at GBX 22. Approximately 189,670 shares changed hands during trading, a decline of 16% from the average session volume of 226,365 shares. The stock had previously closed at GBX 23.

Sareum Stock Down 4.3%

The business’s fifty day moving average is GBX 21.65 and its two-hundred day moving average is GBX 18.29. The stock has a market capitalization of £30.48 million, a PE ratio of -5.64 and a beta of -1.08.

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.